Carboplatin/Paclitaxel Regimen

Identifier: CI-DRUG-00000141
Entity page: /drug/carboplatin-paclitaxel-regimen ↗
Edges: 99

Neighbours: 16 cancers1 variants10 trials
Drawn: 27 of 27 neighbours (cap 60); table lists every fetched edge

Accepted: cancer:<slug>, gene:<symbol>, variant:<slug>, drug:<slug>, trial:<NCT id>, or a bare CI id. Find slugs with search.

Most connectedLung Non-Small Cell Carcinoma 3,147 Malignant Colorectal Neoplasm 1,866 ABL1 298 EGFR 276 Imatinib 450 Dasatinib 321

Neighbourhood

Radial view

Focus at the centre; neighbours grouped by entity type. Click a node to re-centre the graph on it; ↗ opens the entity page. Hover a spoke for relationship, evidence level, cancer context and source.

Edges

Every edge, grouped by relationship

Source-native edges first (aggregated per neighbour, direction, evidence level and source), then derived registry links. Up to 15 per relationship (10 trials); “show all” raises one group to 200.

Relationship	Neighbour	Direction	Evidence level	Cancer context	Support	Claim	Source	Expand
Carboplatin/Paclitaxel Regimen predicts response to …PREDICTS_RESPONSE_TO1 of 1
← predicts response to	Low on-treatment bTMB	sensitivity	B	Lung Squamous Cell Carcinoma	1	Curated	civic	graph →
Carboplatin/Paclitaxel Regimen investigated for …INVESTIGATED_FOR1 of 1
→ investigated for

Carboplatin/Paclitaxel Regimen investigated in trials for …INVESTIGATED_IN_TRIALSderived15 of 38show all (up to 200)
→ investigated in trials for	Lung Non-Small Cell Carcinoma 15 trials (4 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Lung Non-Small Cell Carcinoma	15	Observed	clinicaltrials	graph →
→ investigated in trials for	Malignant Ovarian Neoplasm 6 trials (3 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Malignant Ovarian Neoplasm	6	Observed	clinicaltrials	graph →
→ investigated in trials for	Esophageal Squamous Cell Carcinoma 5 trials (3 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Esophageal Squamous Cell Carcinoma	5	Observed	clinicaltrials	graph →
→ investigated in trials for	Malignant Breast Neoplasm 5 trials (2 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Malignant Breast Neoplasm	5	Observed	clinicaltrials	graph →
→ investigated in trials for	Ovarian Carcinoma 5 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Ovarian Carcinoma	5	Observed	clinicaltrials	graph →
→ investigated in trials for	Carcinoma 3 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Carcinoma	3	Observed	clinicaltrials	graph →
→ investigated in trials for	Malignant Endometrial Neoplasm 3 trials (2 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Malignant Endometrial Neoplasm	3	Observed	clinicaltrials	graph →
→ investigated in trials for	Neoplasm 3 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Neoplasm	3	Observed	clinicaltrials	graph →
→ investigated in trials for	Triple-Negative Breast Carcinoma 3 trials (2 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Triple-Negative Breast Carcinoma	3	Observed	clinicaltrials	graph →
→ investigated in trials for	Fallopian Tube Neoplasm 2 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Fallopian Tube Neoplasm	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Malignant Fallopian Tube Neoplasm 2 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Malignant Fallopian Tube Neoplasm	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Ovarian Neoplasm 2 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Ovarian Neoplasm	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Solid Neoplasm 2 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Solid Neoplasm	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Carcinoma of Unknown Primary 1 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Carcinoma of Unknown Primary	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Endometrial Carcinoma 1 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Endometrial Carcinoma	1	Observed	clinicaltrials	graph →

Carboplatin/Paclitaxel Regimen investigated in trials for …INVESTIGATED_IN_TRIALSderived15 of 38show all (up to 200)

→ investigated in trials for

Lung Non-Small Cell Carcinoma

15 trials (4 active) · conditions mapped to this cancer only (no hierarchy roll-up)

—

Lung Non-Small Cell Carcinoma

Observed

Carboplatin/Paclitaxel Regimen studied in …STUDIED_INderived10 of 59show all (up to 200)
→ studied in	NCT05061550Phase 2 · recruiting Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer · 59 trials list this drug (23 active)	—	—	Lung Non-Small Cell Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07836049Phase 2 · not yet recruiting PhII Study of Toripalimab Followed by Definitive CRT & Adjuvant Toripalimab in Locally Advanced ESCC · 59 trials list this drug (23 active)	—	—	Esophageal Squamous Cell Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07831902Phase 3 · recruiting Refining Adjuvant Treatment IN Endometrial Cancer Based On Molecular Features (RAINBO) - NSMP-ORANGE Trial: Comparing Radiotherapy With Oral Progestin Tablets vs. the Current Standard Care, Radiotherapy and Chemotherapy, in Patients With NSMP Endometrial Cancer · 59 trials list this drug (23 active)	—	—	Uterine Neoplasm,Malignant Endometrial Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT07365319Phase 2/Phase 3 · recruiting A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer. · 59 trials list this drug (23 active)	—	—	Lung Non-Small Cell Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07776171Phase 2 · not yet recruiting Trastuzumab Rezetecan and Carboplatin ± Bevacizumab Versus Investigator's Choice Chemotherapy in Patients With Platinum-sensitive Recurrent Ovarian Cancer · 59 trials list this drug (23 active)	—	—	Malignant Ovarian Neoplasm,Platinum-Sensitive Ovarian Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT02453282Phase 3 · active not recruiting Phase III Open Label First Line Therapy Study of MEDI 4736 (Durvalumab) With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC) · 59 trials list this drug (23 active)	—	—	Lung Non-Small Cell Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT02542293Phase 3 · active not recruiting Study of Durvalumab With Tremelimumab Versus SoC as 1st Line Therapy in Metastatic Non Small-Cell Lung Cancer (NSCLC) (NEPTUNE) · 59 trials list this drug (23 active)	—	—	not mapped	1	Observed	clinicaltrials	graph →
→ studied in	NCT03519971Phase 3 · completed Study of Durvalumab Given With Chemoradiation Therapy in Patients With Unresectable Non-small Cell Lung Cancer · 59 trials list this drug (23 active)	—	—	Lung Non-Small Cell Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07699757Phase 1 · not yet recruiting HSK41959 With Standard Therapy in Solid Tumors With MTAP Deletion · 59 trials list this drug (23 active)	—	—	Solid Neoplasm,Lung Non-Small Cell Carcinoma,Pancreatic Ductal Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT03737643Phase 3 · active not recruiting Durvalumab Treatment in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib Treatment in Advanced Ovarian Cancer Patients · 59 trials list this drug (23 active)	—	—	Malignant Ovarian Neoplasm	1	Observed	clinicaltrials	graph →

Radial view

Every edge, grouped by relationship

Paths